XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by beaniwon Aug 19, 2021 5:13pm

211 Views

Post# 33734871

New C.XRX/XRTXF DD video out

For those asking about the rollback number this video gives you a bit more info as to how it will go (a $4.00 share price (USD I assume) is needed to list on the NASDAQ and NYSE) and some solid information re the company. Sometimes a rollback is indeed a death sentence for early shareholders but other times it is not, in this case it looks to be a good thing. GLTA

https://www.youtube.com/watch?v=UP_ShC6aAmM

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec